Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of GR1802 injection in adults with moderate-to-severe atopic dermatitis
CTR20233857Phase 3Completed
- Sponsor
- Zhixiang Jintai
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of telikibart in atopic dermatitis (AD), sponsored by Zhixiang Jintai. Started Dec 2023; status: completed.
02
Drugs
telikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20233857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233857.